In re: Lipitor Marketing, Sales Practices and Products Liability Litigation
- Case Date: 7/7/2017
- Project Name: Civil Justice Reform
On July 7, 2017, WLF continued its longstanding efforts to promote reliable expert testimony in federal court by filing a brief with the U.S. Court of Appeals for the Fourth Circuit in In re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation. The case arises from a Multi-District Litigation proceeding considering the claims of more than 3,000 plaintiffs who allege that their physician-prescribed use of Lipitor caused them to develop Type-2 diabetes. Seeking affirmance of the trial court’s decision to exclude the plaintiffs’ expert evidence, WLF argues that the district court acted well within its discretion in excluding this expert testimony, without which the plaintiffs did not and could not establish causation. WLF’s brief focused on the importance of maintaining a clear threshold for the reliability of expert evidence, to ensure that junk science does not reach the finder of fact.
More Information and Downloads:
7/7/2017: Download the Brief